SGLT2 inhibitor for kidney stone prevention
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if a diabetes medication (SGLT2i) can help prevent calcium kidney stones. Researchers want to see if it changes the way your urine absorbs and processes minerals.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have had at least one calcium phosphate stone (more than 50% of the stone) or one calcium oxalate stone (more than 50% of the stone).
- You do not have certain other stone types (like uric acid or cysteine stones).
- You do not have severe acid-base problems or very low/high urine citrate levels.
- You can stop taking diuretics or alkali supplements for the study period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach to prevent calcium oxalate kidney stones from coming back. It may help people who have had a procedure to remove stones and have a specific stone type.
This trial tests a medication called SGLT2 inhibitor (a type of diabetes drug that may also help protect the kidneys) in children with chronic kidney disease. It aims to see if the drug is safe and easy to use in children ages 2–18 with moderate to severe kidney problems.
This trial tests if empagliflozin, a diabetes medicine that also protects the kidneys, can help people who have received a kidney transplant. It may be an option if you have reduced kidney function or diabetes after transplant.
This trial tests if a medication called empagliflozin, combined with personalized diet advice, can help prevent kidney stones from coming back. It may be an option if you've had two or more kidney stone events in the last 10 years and your stones were mostly calcium-based.
This study tests if a type 2 diabetes medication (SGLT2 inhibitor) can help people with frequent gout flares. It aims to lower uric acid levels and reduce flare-ups.
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug) can help control calcium and magnesium levels in people with a genetic kidney disease called ADPKD. The goal is to see if it improves kidney health over a short period.
Hear when a new Kidney Stones trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.